

Natural course of distant metastases following radiotherapy in HPV-related oropharyngeal cancer

Oral Oncology

49, 79-85

DOI: [10.1016/j.oraloncology.2012.07.015](https://doi.org/10.1016/j.oraloncology.2012.07.015)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Identification of RNA aptamers that internalize into HPV-16 E6/E7 transformed tonsillar epithelial cells. <i>Virology</i> , 2013, 446, 325-333.	1.1	37
2	Cyclin D1 is a prognostic marker in oropharyngeal squamous cell carcinoma that is tightly associated with high-risk human papillomavirus status. <i>Human Pathology</i> , 2013, 44, 1672-1680.	1.1	21
3	High Frequency of Activating PIK3CA Mutations in Human Papillomavirus-Positive Oropharyngeal Cancer; Mutations in Human PIK3CA in HPV+ Oropharyngeal Squamous Cell Carcinoma. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2013, 139, 617.	1.2	68
4	Clinical management of squamous cell carcinoma of the oropharynx: how does this differ for HPV-related tumors?. <i>Future Oncology</i> , 2013, 9, 1413-1416.	1.1	3
5	Bioactive Lipids S1P and C1P Are Prometastatic Factors in Human Rhabdomyosarcoma, and Their Tissue Levels Increase in Response to Radio/Chemotherapy. <i>Molecular Cancer Research</i> , 2013, 11, 793-807.	1.5	66
6	The current and future impact of human papillomavirus on treatment of squamous cell carcinoma of the head and neck. <i>Annals of Oncology</i> , 2014, 25, 2101-2115.	0.6	70
7	Solitary dural metastasis at presentation in a patient with untreated human papillomavirus-associated squamous cell carcinoma of the oropharynx. <i>Head and Neck</i> , 2014, 36, E103-5.	0.9	10
9	A Quantitative Histomorphometric Classifier (QuHbIC) Identifies Aggressive Versus Indolent p16-Positive Oropharyngeal Squamous Cell Carcinoma. <i>American Journal of Surgical Pathology</i> , 2014, 38, 128-137.	2.1	73
10	New Chapter in Our Understanding of Human Papillomavirus-Related Head and Neck Cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 3349-3352.	0.8	12
11	Distant metastasis in p16-positive oropharyngeal squamous cell carcinoma: A critical analysis of patterns and outcomes. <i>Oral Oncology</i> , 2014, 50, 45-51.	0.8	81
12	Transcriptionally-Active Human Papillomavirus is Consistently Retained in the Distant Metastases of Primary Oropharyngeal Carcinomas. <i>Head and Neck Pathology</i> , 2014, 8, 157-163.	1.3	17
13	Surgically treated oropharyngeal cancer: risk factors and tumor characteristics. <i>Journal of Cancer Research and Clinical Oncology</i> , 2014, 140, 1011-1019.	1.2	16
14	Epidemiology of HPV-associated oropharyngeal cancer. <i>Oral Oncology</i> , 2014, 50, 380-386.	0.8	388
15	Should Patients with HPV-Positive or Negative Tumors be Treated Differently?. <i>Current Oncology Reports</i> , 2014, 16, 384.	1.8	4
17	Human Papillomavirus and Overall Survival After Progression of Oropharyngeal Squamous Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2014, 32, 3365-3373.	0.8	449
18	PET/CT Imaging and Human Papilloma Virus-Positive Oropharyngeal Squamous Cell Cancer: Evolving Clinical Imaging Paradigm. <i>Journal of Nuclear Medicine</i> , 2014, 55, 431-438.	2.8	35
19	Novel treatments for head and neck squamous cell carcinoma: preclinical identification and clinical investigation. <i>Future Oncology</i> , 2014, 10, 1065-1080.	1.1	8
20	Pathogenesis of Infection by Human Papillomavirus. <i>Current Problems in Dermatology</i> , 2014, 45, 47-57.	0.8	9

#	ARTICLE	IF	CITATIONS
21	Long-term survival after distant metastasis in patients with oropharyngeal cancer. <i>Oral Oncology</i> , 2014, 50, 208-212.	0.8	28
22	Inaccuracies in oral cavityâ€“pharynx cancer coded as the underlying cause of death on U.S. death certificates, and trends in mortality rates (1999â€“2010). <i>Oral Oncology</i> , 2014, 50, 732-739.	0.8	7
23	Clinical and scientific impact of human papillomavirus on head and neck cancer. <i>World Journal of Clinical Oncology</i> , 2014, 5, 781.	0.9	44
24	Circulating and disseminated tumour cells in head and neck cancer. <i>Journal of Laryngology and Otology</i> , 2015, 129, 826-830.	0.4	3
25	Extracellular nucleotides as novel, underappreciated pro-metastatic factors that stimulate purinergic signaling in human lung cancer cells. <i>Molecular Cancer</i> , 2015, 14, 201.	7.9	48
26	Longer survival in patients with human papillomavirusâ€“related head and neck cancer after positive postradiation planned neck dissection. <i>Head and Neck</i> , 2015, 37, 946-952.	0.9	14
27	Primary surgery versus (chemo)radiotherapy in oropharyngeal cancer. <i>Current Opinion in Otolaryngology and Head and Neck Surgery</i> , 2015, 23, 139-147.	0.8	22
28	The current role of systemic chemotherapy in the primary treatment of head and neck cancer. <i>Cancer Treatment Reviews</i> , 2015, 41, 217-221.	3.4	24
29	Long-term results of positron emission tomography-directed management of the neck in node-positive head and neck cancer after organ preservation therapy. <i>Oral Oncology</i> , 2015, 51, 260-266.	0.8	24
30	18F FDG PET/CT and Head and Neck Cancer. <i>PET Clinics</i> , 2015, 10, 125-145.	1.5	24
31	Refining American Joint Committee on Cancer/Union for International Cancer Control TNM Stage and Prognostic Groups for Human Papillomavirusâ€“Related Oropharyngeal Carcinomas. <i>Journal of Clinical Oncology</i> , 2015, 33, 836-845.	0.8	345
32	Reply to B. O'Sullivan et al. <i>Journal of Clinical Oncology</i> , 2015, 33, 1708-1709.	0.8	11
33	Soft tissue metastasis in p16-positive oropharynx carcinoma: Prevalence and association with distant metastasis. <i>Oral Oncology</i> , 2015, 51, 778-786.	0.8	27
34	Impact of retropharyngeal adenopathy on distant control and survival in HPV-related oropharyngeal cancer treated with chemoradiotherapy. <i>Radiotherapy and Oncology</i> , 2015, 116, 75-81.	0.3	32
35	The role of postoperative chemoradiation for oropharynx carcinoma: A critical appraisal of the published literature and National Comprehensive Cancer Network guidelines. <i>Cancer</i> , 2015, 121, 1747-1754.	2.0	37
36	Surgical salvage improves overall survival for patients with HPVâ€“positive and HPVâ€“negative recurrent locoregional and distant metastatic oropharyngeal cancer. <i>Cancer</i> , 2015, 121, 1977-1984.	2.0	116
37	A randomized phase II efficacy and correlative studies of cetuximab with or without sorafenib in recurrent and/or metastatic head and neck squamous cell carcinoma. <i>Oral Oncology</i> , 2015, 51, 376-382.	0.8	50
38	Head and Neck Cancer with Metastatic Spread to the Breast. <i>American Journal of Medicine</i> , 2015, 128, e3.	0.6	1

#	ARTICLE	IF	CITATIONS
39	Management of Recurrent HPV-Related Oropharyngeal Cancer. <i>Current Otorhinolaryngology Reports</i> , 2015, 3, 56-62.	0.2	0
40	Effect of Human Papillomavirus on Patterns of Distant Metastatic Failure in Oropharyngeal Squamous Cell Carcinoma Treated With Chemoradiotherapy. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2015, 141, 457.	1.2	104
41	Anticipation of the Impact of Human Papillomavirus on Clinical Decision Making for the Head and Neck Cancer Patient. <i>Hematology/Oncology Clinics of North America</i> , 2015, 29, 1045-1060.	0.9	19
42	Robust Differences in p16-Dependent Oropharyngeal Squamous Cell Carcinoma Distant Metastasis. <i>Otolaryngology - Head and Neck Surgery</i> , 2015, 153, 209-217.	1.1	15
43	First Site of Failure Analysis Incompletely Addresses Issues of Late and Unexpected Metastases in p16-Positive Oropharyngeal Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 1707-1708.	0.8	18
44	Reply to B. O'Sullivan et al. <i>Journal of Clinical Oncology</i> , 2015, 33, 1710-1710.	0.8	6
45	Resection of subsequent pulmonary metastases from treated head and neck squamous cell carcinoma: systematic review and meta-analysis. <i>Clinical Otolaryngology</i> , 2015, 40, 208-218.	0.6	68
46	Treatment deintensification and symptom burden in patients with human papillomavirus-associated head and neck cancer. <i>Cancer</i> , 2015, 121, 1147-1148.	2.0	0
47	Prognostic value of pretreatment circulating neutrophils, monocytes, and lymphocytes in oropharyngeal cancer stratified by human papillomavirus status. <i>Cancer</i> , 2015, 121, 545-555.	2.0	133
48	HPV Associated Head and Neck Cancer. <i>Cancers</i> , 2016, 8, 75.	1.7	96
49	Human Papillomavirus in Head and Neck Cancer. , 0, , .		0
50	Disease-free survival after salvage therapy for recurrent oropharyngeal squamous cell carcinoma. <i>Head and Neck</i> , 2016, 38, E1501-9.	0.9	37
51	Oropharyngeal cancer and human papilloma virus: evolving diagnostic and management paradigms. <i>ANZ Journal of Surgery</i> , 2016, 86, 442-447.	0.3	6
52	Prognostic Value of p16 Status on the Development of a Complete Response in Involved Oropharynx Cancer Neck Nodes After Cisplatin-Based Chemoradiation: A Secondary Analysis of NRG Oncology RTOG 0129. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 362-371.	0.4	22
53	Failure pattern and salvage treatment after radical treatment of head and neck cancer. <i>Acta Oncologica</i> , 2016, 55, 625-632.	0.8	38
54	Impact of p16 expression in oropharyngeal cancer in the postoperative setting: the necessity of re-evaluating traditional risk stratification. <i>Japanese Journal of Clinical Oncology</i> , 2016, 46, 911-918.	0.6	7
55	HPV-related oropharyngeal cancer: Risk factors for treatment failure in patients managed with primary transoral robotic surgery. <i>Head and Neck</i> , 2016, 38, 59-65.	0.9	56
56	Prognostic significance of clinical and ¹⁸ F-FDG PET/CT parameters for post-distant metastasis survival in head and neck squamous cell carcinoma patients. <i>Journal of Surgical Oncology</i> , 2016, 114, 888-894.	0.8	5

#	ARTICLE	IF	CITATIONS
57	Outcomes after surgical salvage for recurrent oropharyngeal squamous cell carcinoma. <i>Oral Oncology</i> , 2016, 60, 118-124.	0.8	27
58	Clinicopathologic characteristics and outcomes of recurrent oropharyngeal squamous cell carcinoma. <i>American Journal of Otolaryngology - Head and Neck Medicine and Surgery</i> , 2016, 37, 513-516.	0.6	0
59	Metastatic HPV-related head and neck squamous cell carcinoma to the lung and mediastinal lymph nodes in aspirated cytology material: A diagnostic pitfall. <i>Diagnostic Cytopathology</i> , 2016, 44, 206-214.	0.5	6
60	Matted nodes as a predictor of distant metastasis in advanced-stage III/IV oropharyngeal squamous cell carcinoma. <i>Head and Neck</i> , 2016, 38, 184-190.	0.9	35
61	A prospective study of positron emission tomography for evaluation of neck node response 6 weeks after radiotherapy in patients with head and neck squamous cell carcinoma. <i>Head and Neck</i> , 2016, 38, E473-9.	0.9	13
62	Salvage surgery for locally recurrent oropharyngeal cancer. <i>Head and Neck</i> , 2016, 38, E658-64.	0.9	66
63	Base of tongue squamous cell carcinoma with infiltrative bone marrow carcinomatosis after definitive chemoradiation: A case report. <i>Head and Neck</i> , 2016, 38, E2449-E2453.	0.9	6
64	Prognostic value of FDG-PET volumetric parameters in patients with p16-positive oropharyngeal squamous cell carcinoma who received curative resection followed by postoperative radiotherapy or chemoradiotherapy. <i>Head and Neck</i> , 2016, 38, 1515-1524.	0.9	11
65	Predictive factors for long-term survival in head and neck squamous cell carcinoma patients with distant metastasis after initial definitive treatment. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 295-304.	1.2	10
66	Elective Nodal Irradiation and Patterns of Failure in Head and Neck Cancer After Primary Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 94, 775-782.	0.4	30
67	Development and validation of a staging system for HPV-related oropharyngeal cancer by the International Collaboration on Oropharyngeal cancer Network for Staging (ICON-S): a multicentre cohort study. <i>Lancet Oncology</i> , The, 2016, 17, 440-451.	5.1	607
68	Understanding the impact of survival and human papillomavirus tumor status on timing of recurrence in oropharyngeal squamous cell carcinoma. <i>Oral Oncology</i> , 2016, 52, 97-103.	0.8	33
69	No benefit for regional control and survival by planned neck dissection in primary irradiated oropharyngeal cancer irrespective of p16 expression. <i>European Archives of Oto-Rhino-Laryngology</i> , 2016, 273, 1841-1848.	0.8	5
70	Emerging insights into recurrent and metastatic human papillomavirus-related oropharyngeal squamous cell carcinoma. <i>Laryngoscope Investigative Otolaryngology</i> , 2017, 2, 10-18.	0.6	54
71	Re-evaluation of Ipsilateral Radiation for T1-T2N0-N2b Tonsil Carcinoma at the Princess Margaret Hospital in the Human Papillomavirus Era, 25 Years Later. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 159-169.	0.4	61
72	Human papillomavirus (HPV) 16 antibodies at diagnosis of HPV-related oropharyngeal cancer and antibody trajectories after treatment. <i>Oral Oncology</i> , 2017, 67, 77-82.	0.8	28
73	High-dose versus weekly cisplatin definitive chemoradiotherapy for HPV-related oropharyngeal squamous cell carcinoma of the head and neck. <i>Oral Oncology</i> , 2017, 67, 24-28.	0.8	12
74	AHNS series: Do you know your guidelines? Management of head and neck cancer in the era of human papillomavirus: Educating our patients on human papillomavirus. <i>Head and Neck</i> , 2017, 39, 833-839.	0.9	7

#	ARTICLE	IF	CITATIONS
75	Management of Recurrent and Metastatic HPV-Positive Oropharyngeal Squamous Cell Carcinoma after Transoral Robotic Surgery. <i>Otolaryngology - Head and Neck Surgery</i> , 2017, 157, 69-76.	1.1	26
76	Predicting two-year longitudinal MD Anderson Dysphagia Inventory outcomes after intensity modulated radiotherapy for locoregionally advanced oropharyngeal carcinoma. <i>Laryngoscope</i> , 2017, 127, 842-848.	1.1	37
77	Influence of human papillomavirus on the clinical presentation of oropharyngeal carcinoma in the United States. <i>Laryngoscope</i> , 2017, 127, 2270-2278.	1.1	36
78	Intravoxel incoherent motion diffusion-weighted MRI during chemoradiation therapy to characterize and monitor treatment response in human papillomavirus head and neck squamous cell carcinoma. <i>Journal of Magnetic Resonance Imaging</i> , 2017, 45, 1013-1023.	1.9	50
79	The role of human papillomavirus on the prognosis and treatment of oropharyngeal carcinoma. <i>Cancer and Metastasis Reviews</i> , 2017, 36, 449-461.	2.7	37
80	Transoral Resection of Human Papillomavirus (HPV)-Positive Squamous Cell Carcinoma of the Oropharynx: Outcomes with and Without Adjuvant Therapy. <i>Annals of Surgical Oncology</i> , 2017, 24, 3494-3501.	0.7	24
81	A Comparison of Prognostic Ability of Staging Systems for Human Papillomavirus-Related Oropharyngeal Squamous Cell Carcinoma. <i>JAMA Oncology</i> , 2017, 3, 358.	3.4	44
82	Human Papillomavirus (HPV): A Criterion for Therapeutic Decision in Squamous Cell Carcinoma of the Head and Neck?. <i>Recent Results in Cancer Research</i> , 2017, 206, 137-147.	1.8	7
83	Systemic Treatment in HPV-Induced Recurrent or Metastatic HNSCC. <i>Recent Results in Cancer Research</i> , 2017, 206, 149-160.	1.8	2
84	Molecular Imaging and Precision Medicine in Head and Neck Cancer. <i>PET Clinics</i> , 2017, 12, 7-25.	1.5	7
85	Vertically transmitted HPV-dependent squamous cell carcinoma of the external auditory canal. <i>Strahlentherapie Und Onkologie</i> , 2017, 193, 156-161.	1.0	5
86	Orbital Mass as First Presentation of Metastatic p16-Positive Oropharyngeal Squamous Cell Carcinoma. <i>Current Oncology</i> , 2017, 24, 551-554.	0.9	4
87	HPV impacts survival of stage IVC non-oropharyngeal HNSCC cancer patients. <i>Otorhinolaryngology-head and Neck Surgery</i> , 2017, 2, .	0.1	8
88	Radiomic Biomarkers to Refine Risk Models for Distant Metastasis in HPV-related Oropharyngeal Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 1107-1116.	0.4	57
89	Approach to oligometastatic disease in head and neck cancer, on behalf of the GORTEC. <i>Future Oncology</i> , 2018, 14, 877-889.	1.1	31
90	Survival outcomes following salvage surgery for oropharyngeal squamous cell carcinoma: systematic review. <i>Journal of Laryngology and Otology</i> , 2018, 132, 299-313.	0.4	19
91	Application of the Eighth Edition American Joint Committee on Cancer Staging System for HPV-Related Oropharyngeal Cancer Treated With Transoral Robotic Surgery. <i>Laryngoscope</i> , 2018, 128, 1133-1139.	1.1	8
92	An Algorithm to Evaluate Suspected Lung Metastases in Patients with HPV-Associated Oropharyngeal Cancer. <i>Otolaryngology - Head and Neck Surgery</i> , 2018, 158, 118-121.	1.1	4

#	ARTICLE	IF	CITATIONS
93	Current Status and Future Directions of Treatment Deintensification in Human Papilloma Virus-associated Oropharyngeal Squamous Cell Carcinoma. <i>Seminars in Radiation Oncology</i> , 2018, 28, 27-34.	1.0	29
94	The Current State of Biological and Clinical Implications of Human Papillomavirus-Related Oropharyngeal Cancer. <i>Seminars in Radiation Oncology</i> , 2018, 28, 17-26.	1.0	16
95	Locally advanced high-risk HPV related oropharyngeal squamous cell carcinoma (OPSCC); have we forgotten it is a different disease?. <i>Cancers of the Head & Neck</i> , 2018, 3, 8.	6.2	3
96	Extracellular vesicle microRNA cargo is correlated with HPV status in oropharyngeal carcinoma. <i>Journal of Oral Pathology and Medicine</i> , 2018, 47, 954-963.	1.4	24
97	HPV status predicts for improved survival following chemotherapy in metastatic squamous cell carcinoma of the oropharynx. <i>Oral Oncology</i> , 2018, 86, 69-74.	0.8	4
98	Post-operative radiation effects on lymphopenia, neutrophil to lymphocyte ratio, and clinical outcomes in palatine tonsil cancers. <i>Oral Oncology</i> , 2018, 86, 1-7.	0.8	27
99	Oligometastatic status as predictor of survival in metastatic human papillomavirus-positive oropharyngeal carcinoma. <i>Head and Neck</i> , 2018, 40, 1685-1690.	0.9	25
100	HPV –“ Das andere Kopf-Hals-Karzinom. <i>Laryngo- Rhino- Otologie</i> , 2018, 97, S48-S113.	0.2	35
101	Pattern of and survival following loco-regional and distant recurrence in patients with HPV+ and HPV- oropharyngeal squamous cell carcinoma: A population-based study. <i>Oral Oncology</i> , 2018, 83, 127-133.	0.8	39
102	Atypical Metastasis of p16-Positive Tonsillar Squamous Cell Carcinoma to the Pleura: A Case Report. <i>Journal of Oral and Maxillofacial Surgery</i> , 2018, 76, 2577-2581.	0.5	1
103	Plasma HPV cell-free DNA monitoring in advanced HPV-associated oropharyngeal cancer. <i>Annals of Oncology</i> , 2018, 29, 1980-1986.	0.6	94
104	Association of Symptoms and Clinical Findings With Anticipated Outcomes in Patients With Recurrent Head and Neck Cancer. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2018, 144, 738.	1.2	4
105	Cavernous sinus involvement in human papillomavirus associated oropharyngeal squamous cell carcinoma: Case report of an atypical site of distant metastasis. <i>Journal of Otolaryngology - Head and Neck Surgery</i> , 2018, 47, 32.	0.9	4
106	Surgery- vs Radiation-Based Therapy for p16+/HPV-Related Oropharyngeal Cancers. <i>Current Otorhinolaryngology Reports</i> , 2018, 6, 298-309.	0.2	4
107	Radiologic predictors of immune checkpoint inhibitor response in advanced head and neck squamous cell carcinoma. <i>Oral Oncology</i> , 2018, 85, 29-34.	0.8	15
108	Brain metastasis from squamous cell carcinoma of the head and neck: a review of the literature in the genomic era. <i>Neurosurgical Focus</i> , 2018, 44, E11.	1.0	15
110	Advanced HPV-Related Oropharynx Cancer. , 2018, , 677-699.		0
111	Clinical and Molecular Characterization of Surgically Treated Oropharynx Squamous Cell Carcinoma Samples. <i>Pathology and Oncology Research</i> , 2019, 25, 1047-1058.	0.9	11

#	ARTICLE	IF	CITATIONS
112	Modern radiotherapy for head and neck cancer. <i>Seminars in Oncology</i> , 2019, 46, 233-245.	0.8	147
113	Treatment outcomes in oropharynx cancer patients who did not complete planned curative radiotherapy. <i>Oral Oncology</i> , 2019, 97, 124-130.	0.8	2
114	Head and Neck Cancers. , 2019, , 133-196.		0
115	<p>Role of radiotherapy in the treatment of metastatic head and neck cancer</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 677-683.	1.0	22
116	The addition of chemotherapy to radiotherapy did not reduce the rate of distant metastases in low-risk HPV-related oropharyngeal cancer in a real-world setting. <i>Head and Neck</i> , 2019, 41, 2271-2276.	0.9	8
117	Point/Counterpoint: Do We De-escalate Treatment of HPV-Associated Oropharynx Cancer Now? And How?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 364-372.	1.8	26
118	Clinical outcome of stereotactic body radiotherapy for lung-only oligometastatic head and neck squamous cell carcinoma: Is the deferral of systemic therapy a potential goal?. <i>Oral Oncology</i> , 2019, 93, 1-7.	0.8	32
119	<p>Novel genetic alterations and their impact on target therapy response in head and neck squamous cell carcinoma</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 1321-1336.	0.9	19
120	Impact of American Joint Committee on Cancer Eighth Edition clinical stage and smoking history on oncologic outcomes in human papillomavirus-associated oropharyngeal squamous cell carcinoma. <i>Head and Neck</i> , 2019, 41, 857-864.	0.9	28
121	A Hidden Epidemic of Intermediate Risk Oropharynx Cancer. <i>Laryngoscope Investigative Otolaryngology</i> , 2019, 4, 617-623.	0.6	11
122	The emergence of long-term survivors in recurrent and metastatic squamous cell head and neck cancer. <i>Current Opinion in Oncology</i> , 2019, 31, 160-168.	1.1	3
123	Outcomes of relapsed human papillomavirus-related oropharyngeal squamous cell carcinoma treated with curative intent. <i>Head and Neck</i> , 2019, 41, 1312-1319.	0.9	10
124	Systematic review on location and timing of distant progression in human papillomavirus-positive and human papillomavirus-negative oropharyngeal squamous cell carcinomas. <i>Head and Neck</i> , 2019, 41, 793-798.	0.9	15
125	Tumor microenvironment modulation enhances immunologic benefit of chemoradiotherapy. , 2019, 7, 10.		66
126	Reply to "Do not de-escalate oncology care in oropharyngeal cancer routinely". <i>Head and Neck</i> , 2020, 42, 145-146.	0.9	0
127	Disease course after the first recurrence of head and neck squamous cell carcinoma following (chemo)radiation. <i>European Archives of Oto-Rhino-Laryngology</i> , 2020, 277, 261-268.	0.8	11
128	Do not de-escalate oncology care in oropharyngeal cancer routinely. <i>Head and Neck</i> , 2020, 42, 143-144.	0.9	0
129	Metachronous mediastinal and lung metastases from head and neck cancer: A case series, literature review and considerations for treatment. <i>Oral Oncology</i> , 2020, 102, 104518.	0.8	2

#	ARTICLE	IF	CITATIONS
130	The P2X7 Receptor in the Maintenance of Cancer Stem Cells, Chemoresistance and Metastasis. Stem Cell Reviews and Reports, 2020, 16, 288-300.	1.7	30
131	Management of recurrent and metastatic oral cavity cancer: Raising the bar a step higher. Oral Oncology, 2020, 101, 104492.	0.8	44
132	Pathologic response to neoadjuvant chemotherapy in HPV-associated oropharynx cancer. Head and Neck, 2020, 42, 417-425.	0.9	28
133	Unique Patterns of Distant Metastases in HPV-Positive Head and Neck Cancer. Oncology, 2020, 98, 179-185.	0.9	20
134	Pathological and Virological Studies of p16-Positive Oropharyngeal Carcinoma with a Good Response to Neoadjuvant Chemotherapy. Microorganisms, 2020, 8, 1497.	1.6	2
135	Locoregional and distant recurrence for HPV-associated oropharyngeal cancer using AJCC 8 staging. Oral Oncology, 2020, 111, 105030.	0.8	7
136	Oligometastatic Disease Management: Finding the Sweet Spot. Frontiers in Oncology, 2020, 10, 617793.	1.3	13
137	p16-positive oropharyngeal cancer with rare thyroid metastasis: A case report. Journal of Medical Investigation, 2020, 67, 189-191.	0.2	2
138	De-intensification of treatment in human papilloma virus related oropharyngeal carcinoma: Patient choice still matters for de-escalation and for the COVID era. Oral Oncology, 2020, 105, 104768.	0.8	1
139	Follow-Up of Head and Neck Cancer Survivors: Tipping the Balance of Intensity. Frontiers in Oncology, 2020, 10, 688.	1.3	20
140	Radiation therapy for oligometastatic oropharyngeal cancer. BJR case Reports, 2020, 6, 20190021.	0.1	2
141	Neoadjuvant chemotherapy followed by surgery for HPV-associated locoregionally advanced oropharynx cancer. Head and Neck, 2020, 42, 2145-2154.	0.9	23
142	Oligometastatic head and neck cancer: Comprehensive review. Head and Neck, 2020, 42, 2194-2201.	0.9	30
143	Novel Strategies to Effectively De-escalate Curative-Intent Therapy for Patients With HPV-Associated Oropharyngeal Cancer: Current and Future Directions. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2020, 40, 257-269.	1.8	18
145	Surveillance Outcomes and Intensity of Salvage Therapy Among Human Papillomavirus-Associated Oropharyngeal Cancers. JAMA Otolaryngology - Head and Neck Surgery, 2020, 146, 311.	1.2	0
146	Human Papillomavirus and carcinogenesis: Novel mechanisms of cell communication involving extracellular vesicles. Cytokine and Growth Factor Reviews, 2020, 51, 92-98.	3.2	14
147	Plasma Circulating Tumor HPV DNA for the Surveillance of Cancer Recurrence in HPV-Associated Oropharyngeal Cancer. Journal of Clinical Oncology, 2020, 38, 1050-1058.	0.8	219
148	Fluorodeoxyglucose positron emission tomography/computed tomography identifying pericardial metastasis from early-stage p16-positive oropharyngeal cancer. Clinical Case Reports (discontinued), 2020, 8, 1261-1264.	0.2	1

#	ARTICLE	IF	CITATIONS
149	“Good cancer gone bad”™: a narrative review of HPV oropharyngeal cancer and potential poor outcomes. <i>European Archives of Oto-Rhino-Laryngology</i> , 2020, 277, 2185-2191.	0.8	9
150	Clinical features of head and neck cancer patients with brain metastases: A retrospective study of 88 cases. <i>Oral Oncology</i> , 2021, 112, 105086.	0.8	1
151	Radiotherapy in Metastatic Oropharyngeal Cancer. <i>Laryngoscope</i> , 2021, 131, E1847-E1853.	1.1	1
152	Oropharyngeal cancer: First relapse description and prognostic factor of salvage treatment according to p16 status, a GETTEC multicentric study. <i>European Journal of Cancer</i> , 2021, 143, 168-177.	1.3	13
153	Prognostic Significance of Extranodal Extension in HPV-Mediated Oropharyngeal Carcinoma: A Systematic Review and Meta-Analysis. <i>Otolaryngology - Head and Neck Surgery</i> , 2021, 164, 720-732.	1.1	28
154	Mutation patterns in recurrent and/or metastatic oropharyngeal squamous cell carcinomas in relation to human papillomavirus status. <i>Cancer Medicine</i> , 2021, 10, 1347-1356.	1.3	9
156	Impacts of Environmental Factors on Head and Neck Cancer Pathogenesis and Progression. <i>Cells</i> , 2021, 10, 389.	1.8	42
157	Metastatic human papillomavirus-positive oropharyngeal carcinoma mimicking primary cutaneous sweat-gland carcinoma. <i>Journal of Cutaneous Pathology</i> , 2021, 48, 818-820.	0.7	0
158	Nodal staging convergence for HPV ⁻ and HPV ⁺ oropharyngeal carcinoma. <i>Cancer</i> , 2021, 127, 1590-1597.	2.0	8
159	Characterizing distant metastases and survival in oropharyngeal squamous cell carcinoma. <i>Head and Neck</i> , 2021, 43, 2101-2109.	0.9	10
160	cfDNA detection for HPV ⁺ squamous cell carcinomas. <i>Oral Oncology</i> , 2021, 115, 104958.	0.8	18
161	External validation of OroGrams as a predictive model for overall and progression-free survival in Scottish patients with oropharyngeal squamous cell carcinoma: a retrospective cohort study. <i>British Journal of Oral and Maxillofacial Surgery</i> , 2021, 59, 368-374.	0.4	0
162	Distinct Outcomes of Oropharyngeal Squamous Cell Carcinoma Patients after Distant Failure According to p16 Status: Implication in Therapeutic Options. <i>Current Oncology</i> , 2021, 28, 1673-1680.	0.9	6
163	Identification of High-Risk Human Papillomavirus DNA, p16, and E6/E7 Oncoproteins in Laryngeal and Hypopharyngeal Squamous Cell Carcinomas. <i>Viruses</i> , 2021, 13, 1008.	1.5	5
164	Pre-treatment PET/MRI based FDG and DWI imaging parameters for predicting HPV status and tumor response to chemoradiotherapy in primary oropharyngeal squamous cell carcinoma (OPSCC). <i>Oral Oncology</i> , 2021, 116, 105239.	0.8	11
165	Long-Term Survival and Recurrence in Oropharyngeal Squamous Cell Carcinoma in Relation to Subsites, HPV, and p16-Status. <i>Cancers</i> , 2021, 13, 2553.	1.7	18
166	Cell-Free Human Papillomavirus DNA for Monitoring Treatment Response of Head and Neck Squamous Cell Carcinoma: Systematic Review and Meta-Analysis. <i>Laryngoscope</i> , 2022, 132, 560-568.	1.1	14
167	The Role of Immunotherapy to Overcome Resistance in Viral-Associated Head and Neck Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 649963.	1.3	4

#	ARTICLE	IF	CITATIONS
168	Dissemination patterns and chronology of distant metastasis affect survival of patients with head and neck squamous cell carcinoma. <i>Oral Oncology</i> , 2021, 119, 105356.	0.8	7
169	Distant metastases in squamous cell carcinoma of the pharynx and larynx: a population-based DAHANCA study. <i>Acta Oncol</i> , 2021, 60, 1472-1480.	0.8	3
170	Profiling of extracellular vesicles in oral cancer, from transcriptomics to proteomics. <i>Seminars in Cancer Biology</i> , 2021, 74, 3-23.	4.3	13
171	Advances in Imaging for HPV-Related Oropharyngeal Cancer: Applications to Radiation Oncology. <i>Seminars in Radiation Oncology</i> , 2021, 31, 371-388.	1.0	16
172	Definitive tumor directed therapy confers a survival advantage for metachronous oligometastatic HPV-associated oropharyngeal cancer following trans-oral robotic surgery. <i>Oral Oncology</i> , 2021, 121, 105509.	0.8	8
173	Molecular Features and Treatment Modalities of "Classic" Versus Human Papilloma Virus-Associated Head and Neck Cancer. , 2014, , 7-21.		2
174	Improved outcomes in PI3K-pathway-altered metastatic HPV oropharyngeal cancer. <i>JCI Insight</i> , 2018, 3, .	2.3	21
175	The prognostic impact of human papillomavirus status following treatment failure in oropharyngeal cancer. <i>PLoS ONE</i> , 2017, 12, e0181108.	1.1	10
176	Metastatic disease in head & neck oncology. <i>Acta Otorhinolaryngologica Italica</i> , 2020, 40, S1-S86.	0.7	83
177	Bone Marrow Failure in HPV-Associated Oropharyngeal Squamous Cell Carcinoma. <i>Journal of Otolaryngology-ENT Research</i> , 2018, 10, .	0.1	2
178	Surveillance Imaging in HPV-related Oropharyngeal Cancer. <i>Anticancer Research</i> , 2018, 38, 1525-1529.	0.5	9
179	Is pulmonary metastasectomy beneficial in head and neck squamous cell carcinoma? A review of literature. <i>Indian Journal of Cancer</i> , 2017, 54, 2.	0.2	4
180	Patterns of Distant Failure and Second Primary Cancers in Patients with Oropharyngeal Squamous Cell Carcinoma: Implications for Surveillance Methodology. <i>Journal of Cancer Research Updates</i> , 2014, 3, .	0.3	2
181	The Key Differences between Human Papillomavirus-Positive and -Negative Head and Neck Cancers: Biological and Clinical Implications. <i>Cancers</i> , 2021, 13, 5206.	1.7	30
182	HPV status and therapeutic initial strategy impact on survival and oncologic outcomes: 5-year results from the multicentric prospective cohort of oropharyngeal cancers Papillophar. <i>European Archives of Oto-Rhino-Laryngology</i> , 2022, 279, 3071-3078.	0.8	3
184	Clinical Presentation of HPV-Driven Oropharyngeal Carcinoma. , 2015, , 195-212.		0
185	The clinical aspects of HPV-positive cancer of the oral cavity and oropharynx. <i>Vestnik Otorinolaringologii</i> , 2016, 81, 72.	0.0	5
186	Oropharyngeal Cancer and HPV. <i>Practica Otologica</i> , 2016, 109, 371-381.	0.0	0

#	ARTICLE	IF	CITATIONS
187	Treatment of Viral-Associated HNC (OPC and NPC). , 2017, , 177-188.		0
188	Recurrent/Metastatic Head and Neck Cancer: When and How to Irradiate. , 2017, , 209-219.		0
189	Impact of Different Treatment Concepts on Regional Failure in Advanced Oropharyngeal Cancer. Anticancer Research, 2017, 37, 727-734.	0.5	0
190	Clinical features of death cases in human papillomavirus related oropharyngeal carcinoma. Japanese Journal of Head and Neck Cancer, 2019, 45, 397-402.	0.0	0
191	PET in the Diagnosis of Head and Neck Cancer. , 2020, , 187-221.		0
192	Most Survivors of Head and Neck Cancer Should Be Offered Lung Cancer Screening. JAMA Otolaryngology - Head and Neck Surgery, 2021, 147, 1078.	1.2	2
193	Neoplasms of the Oral Cavity and Oropharynx. , 2021, , 427-447.		0
194	Risk stratification after recurrence of human papillomavirus (HPV) â€related and nonâ€HPV â€related oropharyngeal cancer: A secondary analysis of NRG Oncology RTOG 0129 and 0522. Head and Neck, 2021, 44, 158.	0.9	3
196	The prognosis of HPV-associated metastatic pharyngeal patients by primary and distant site. Oral Oncology, 2022, 125, 105675.	0.8	8
197	Increasing HPV vaccination coverage to prevent oropharyngeal cancer: A cost-effectiveness analysis. Tumour Virus Research, 2022, 13, 200234.	1.5	4
198	Evolution of a Paradigm Switch in Diagnosis and Treatment of HPV-Driven Head and Neck Cancerâ€”Striking the Balance Between Toxicity and Cure. Frontiers in Pharmacology, 2021, 12, 753387.	1.6	10
199	Unfinished Business in Classifying HPV-Positive Oropharyngeal Carcinoma: Identifying the Bad Apples in a Good Staging Barrel. Oncologist, 2022, 27, 4-6.	1.9	4
200	Curative intent Stereotactic Ablative Radiation Therapy (SABR) for treatment of lung oligometastases from head and neck squamous cell carcinoma (HNSCC): a multi-institutional retrospective study. British Journal of Radiology, 2022, 95, 20210033.	1.0	5
201	PET/Computed Tomography. PET Clinics, 2022, 17, 319-326.	1.5	6
202	Development and Validation of a Decision Analytical Model for Posttreatment Surveillance for Patients With Oropharyngeal Carcinoma. JAMA Network Open, 2022, 5, e227240.	2.8	3
203	Long term survival in patients with human papillomavirus-positive oropharyngeal cancer and equivocal response on 12-week PET-CT is not compromised by the omission of neck dissection. Oral Oncology, 2022, 128, 105870.	0.8	2
204	Detection of Occult Recurrence Using Circulating Tumor Tissue Modified Viral HPV DNA among Patients Treated for HPV-Driven Oropharyngeal Carcinoma. Clinical Cancer Research, 2022, 28, 4292-4301.	3.2	45
205	Cecal mass: An unusual site of metastasis from HPV-associated oropharyngeal cancer. Oral Oncology, 2022, 130, 105928.	0.8	0

#	ARTICLE	IF	CITATIONS
206	De-Escalation Strategies for Human Papillomavirus-Associated Oropharyngeal Squamous Cell Carcinoma—Where Are We Now?. <i>Current Oncology</i> , 2022, 29, 3668-3697.	0.9	8
207	Palliative tumor surgery for incurable head and neck cancer: indications and outcomes: A retrospective case review. <i>Precision and Future Medicine</i> , 2022, 6, 146-153.	0.5	0
208	Current perspectives on recurrent HPV-mediated oropharyngeal cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	11
209	Importance of lymph node ratio in HPV-related oropharyngeal cancer patients treated with surgery and adjuvant treatment. <i>PLoS ONE</i> , 2022, 17, e0273059.	1.1	2
210	Oligometastatic Head and Neck Cancer: Challenges and Perspectives. <i>Cancers</i> , 2022, 14, 3894.	1.7	9
211	Distant metastases in human papillomavirus-related oropharyngeal squamous cell carcinoma: Systematic review and meta-analysis. <i>Head and Neck</i> , 0, , .	0.9	2
212	Consensuses, controversies, and future directions in treatment deintensification for human papillomavirus-associated oropharyngeal cancer. <i>Ca-A Cancer Journal for Clinicians</i> , 2023, 73, 164-197.	157.7	16
213	Individualization of treatment policy for patients with regional metastatic oropharyngeal carcinoma associated with human papillomavirus. <i>Onkologiya Zhurnal Imeni P A Gertsena</i> , 2022, 11, 65.	0.0	0
214	Clinical Uncertainties of Circulating Tumor DNA in Human Papillomavirus-Related Oropharyngeal Squamous Cell Carcinoma in the Absence of National Comprehensive Cancer Network Guidelines. <i>Journal of Clinical Oncology</i> , 2023, 41, 2483-2487.	0.8	6
215	Utility of PET-CT in Newly Diagnosed HPV-Associated Oropharyngeal Squamous Cell Carcinoma. <i>Annals of Otolaryngology, Rhinology and Laryngology</i> , 0, , 000348942211359.	0.6	0
216	Practical Application of Circulating Tumor-Related DNA of Human Papillomavirus in Liquid Biopsy to Evaluate the Molecular Response in Patients with Oropharyngeal Cancer. <i>Cancers</i> , 2023, 15, 1047.	1.7	2
217	The oligometastatic setting in HNSCC: A critical review by the Rete Oncologica Piemonte e Valle d'Aosta multidisciplinary team. <i>Critical Reviews in Oncology/Hematology</i> , 2023, 185, 103968.	2.0	2
218	Analytical Validation of NavDx, a cfDNA-Based Fragmentomic Profiling Assay for HPV-Driven Cancers. <i>Diagnostics</i> , 2023, 13, 725.	1.3	9
219	Examination of optimal initial treatment for Stage p16-positive oropharyngeal squamous cell carcinoma. <i>Journal of Japan Society for Head and Neck Surgery</i> , 2023, 32, 245-250.	0.0	0
220	Assessment of the Mutation Profile of Tonsillar Squamous Cell Carcinomas Using Targeted Next-Generation Sequencing. <i>Biomedicines</i> , 2023, 11, 851.	1.4	2
221	Systemic Treatment Sequencing and Prediction of First-line Therapy Outcomes in Recurrent or Metastatic Head and Neck Cancer. , 2023, , 199-215.		0
222	Oropharyngeal squamous cell carcinoma: Prognostic factors for development of distant metastases and oncological outcomes. <i>Head and Neck</i> , 2023, 45, 1406-1417.	0.9	2
223	Personalizing Surveillance in Head and Neck Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2023, , .	1.8	6

#	ARTICLE	IF	CITATIONS
226	Clinical, morphologic and molecular heterogeneity of HPV-associated oropharyngeal cancer. <i>Oncogene</i> , 2023, 42, 2939-2955.	2.6	1